Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C

AIDS. 2013 Nov 13;27(17):2817-9. doi: 10.1097/01.aids.0000433234.78807.54.

Abstract

The IFNL4 ss469415590 polymorphism has recently be shown to better predict treatment response in chronic hepatitis than the IL28B rs12979860 variant. However, no data exist in patients with HIV/hepatitis C virus (HCV) coinfection. Analysing 206 HCV(+)/HIV(+) and 162 HCV(+)/HIV(-) patients, we found that compared with IL28B rs12979860, IFNL4 ss469415590 was strongly associated with response to interferon/ribavirin therapy in HCV(+)/HIV(-) individuals but not in HIV(+)/HCV(+) patients. Thus, effects of the IFNL4 variant may differ in HIV(+) and HIV(-) patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Female
  • Genotype
  • HIV Infections / complications*
  • Hepatitis C / drug therapy*
  • Humans
  • Interferons / therapeutic use*
  • Interleukins / genetics*
  • Male
  • Middle Aged
  • Polymorphism, Genetic*
  • Ribavirin / therapeutic use
  • Treatment Outcome

Substances

  • Antiviral Agents
  • IFNL4 protein, human
  • Interleukins
  • Ribavirin
  • Interferons